For the quarter ending 2026-03-31, LUNG had -$8,180K decrease in cash & cash equivalents over the period. -$10,106K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -13,654 | -10,425 | -13,957 | -29,621 |
| Stock-based compensation expense | 4,136 | 4,241 | 5,166 | 11,826 |
| Impairment of capitalized software development costs | - | 0 | 0 | 0 |
| Change in allowance for credit losses | - | 0 | 0 | 0 |
| Inventory write-down (recovery), net | 144 | 167 | 72 | -96 |
| Depreciation and amortization expense | 220 | 231 | 246 | 577 |
| Loss on extinguishment of debt | -107 | - | - | - |
| Amortization of debt discount and debt issuance costs | 46 | 15 | 14 | 24 |
| Pik interest incurred but not paid on term loan | 67 | - | - | - |
| Net accretion of discounts on marketable securities | 0 | 0 | 40 | 339 |
| Non-cash lease expense | 415 | 368 | 465 | 615 |
| Accounts receivable | -1,204 | -1,606 | -1,410 | 1,941 |
| Inventory | 959 | 810 | 1,021 | -1,066 |
| Prepaid expenses and other current assets | 29 | -627 | 913 | -1,099 |
| Other assets | -61 | -95 | -122 | 359 |
| Accounts payable | -430 | -2,496 | 121 | 2,645 |
| Accrued liabilities | -1,165 | -443 | 528 | -2,364 |
| Income taxes payable | 51 | 109 | -7 | 92 |
| Lease liabilities | -329 | -281 | -381 | -293 |
| Deferred tax liability | -4 | 15 | - | - |
| Deferred revenue | 14 | -73 | 13 | -61 |
| Net cash used in operating activities | -10,097 | -7,084 | -8,162 | -17,130 |
| Purchases of investments | 0 | 0 | 0 | 5,651 |
| Maturities of investments | 0 | 0 | 8,800 | 27,785 |
| Purchases of property and equipment and internal software development costs | 9 | 13 | 89 | 350 |
| Net cash (used in) provided by investing activities | -9 | -13 | 8,711 | 21,784 |
| Repayment of credit agreement | - | 51 | 1 | 48 |
| Repayment of debt | 37,000 | - | - | - |
| Debt issuance cost | - | 0 | 23 | 47 |
| Proceeds from debt | 38,785 | - | - | - |
| Proceeds from exercise of common stock options | 40 | 106 | 5 | 138 |
| Proceeds from issuance of common stock under the employee stock purchase plan | 201 | 0 | 200 | 554 |
| Net cash provided by financing activities | 2,026 | 55 | 181 | 597 |
| Effect of exchange rate changes on cash and cash equivalents | -100 | 241 | 355 | -688 |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | -8,180 | -6,801 | 1,085 | 4,563 |
| Cash, cash equivalents, and restricted cash at beginning of the period | 70,009 | 76,810 | 71,162 | - |
| Cash, cash equivalents, and restricted cash at end of the period | 61,829 | 70,009 | 76,810 | - |